News Releases | Subscribe

February 22, 2019

Vectra® Study Published in the Journal Current Medical Research & Opinion

Vectra Test Significantly Outperforms DAS28-CRP and CRP and Is the Best Predictor of Joint Damage in Patients with Rheumatoid Arthritis SALT LAKE CITY, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication

Read More

February 15, 2019

Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer

SALT LAKE CITY, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced its support of the American Society of Breast Surgeons (ASBrS) new guidelines that recommend all people diagnosed with breast cancer undergo genetic

Read More

February 13, 2019

Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at multiple upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer at Myriad Genetics will

Read More

February 5, 2019

Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

Total Second-Quarter Revenues of $216.8 Million, Up 15 Percent Second-Quarter Diluted EPS of $0.03 and Adjusted EPS of $0.38, Up 6 Percent SALT LAKE CITY, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and

Read More

November 19, 2018

Myriad Announces $50 Million Accelerated Share Repurchase Program

SALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A.

Read More

November 6, 2018

Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results

Total First-Quarter Revenues of $202.3 Million, Up 13 Percent First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent Revised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of $1.70 to $1.75 SALT

Read More

February 13, 2019

Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at multiple upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer at Myriad Genetics will

Read More

January 28, 2019

Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019

SALT LAKE CITY, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal second-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

December 31, 2018

Peter D. Meldrum (1947-2018)

Myriad Salutes the Life and Achievements of Its Co-Founder SALT LAKE CITY, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that the company’s former CEO Peter Durkee Meldrum, age 71, passed away on Thursday, December 20, 2018.

Read More

February 22, 2019

Vectra® Study Published in the Journal Current Medical Research & Opinion

Vectra Test Significantly Outperforms DAS28-CRP and CRP and Is the Best Predictor of Joint Damage in Patients with Rheumatoid Arthritis SALT LAKE CITY, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication

Read More

February 15, 2019

Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer

SALT LAKE CITY, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced its support of the American Society of Breast Surgeons (ASBrS) new guidelines that recommend all people diagnosed with breast cancer undergo genetic

Read More

February 11, 2019

Myriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs

Enhanced Test Improves Detection of Chromosomal Abnormalities by 30 Percent(1) SALT LAKE CITY, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health subsidiary has enhanced the Prequel TM

Read More

February 22, 2019

Vectra® Study Published in the Journal Current Medical Research & Opinion

Vectra Test Significantly Outperforms DAS28-CRP and CRP and Is the Best Predictor of Joint Damage in Patients with Rheumatoid Arthritis SALT LAKE CITY, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication

Read More

February 11, 2019

Myriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs

Enhanced Test Improves Detection of Chromosomal Abnormalities by 30 Percent(1) SALT LAKE CITY, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health subsidiary has enhanced the Prequel TM

Read More

February 8, 2019

Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting

SALT LAKE CITY, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that its Myriad Women’s Health business unit will present new data from eight studies at the 2019 Society for Maternal-Fetal

Read More

Myriad Corporate Presentation
Fact Sheet
Company Milestones